Aspirin News and Research RSS Feed - Aspirin News and Research

Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

PuraMed BioScience, Inc., a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic M, has "robust efficacy". [More]
Study analyzes potential usefulness of new treatment to reopen clogged arteries

Study analyzes potential usefulness of new treatment to reopen clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. [More]

PCF funds two new Young Investigators in China to lead research projects on prostate cancer

The Prostate Cancer Foundation today announced that it is funding two more Young Investigators in China to lead innovative research projects within the country and expand PCF's global knowledge exchange on game-changing research in prostate cancer. [More]
Review for clinicians on optimal utilization of aspirin to treat, prevent heart attacks published

Review for clinicians on optimal utilization of aspirin to treat, prevent heart attacks published

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University published a review for clinicians on the optimal utilization of aspirin to treat and prevent heart attacks. [More]
POZEN announces revenue of $1.4 million for first quarter 2013

POZEN announces revenue of $1.4 million for first quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2013. [More]
Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation. [More]
Viewpoints: Liberals refuse to acknowledge evidence of Oregon Medicaid study; Politics is roiling science in emergency contraception decisions

Viewpoints: Liberals refuse to acknowledge evidence of Oregon Medicaid study; Politics is roiling science in emergency contraception decisions

A familiar critique of liberal governance is that the results always matter less than its grand social ambitions. The latest evidence of this truth comes in the reaction to disappointing new findings from one of the most important public-policy experiments since the 1970s. A team of varsity health economists, mostly at Harvard and MIT, is studying the relationship between health outcomes and health insurance delivered by Medicaid (5/2). [More]
Researchers awarded grant to reduce higher rates of stroke among underserved populations

Researchers awarded grant to reduce higher rates of stroke among underserved populations

UCLA researchers and their partners across Los Angeles County have been awarded an $11 million grant to fund research on community-based interventions to reduce the higher rates of stroke and death from stroke among disadvantaged Hispanics, African Americans and Asian-Americans. [More]
Taking painkillers before race leads to unrecognised problems

Taking painkillers before race leads to unrecognised problems

Many competitors try to prevent pain interfering with their performance by taking painkillers that are readily available in pharmacies and supermarkets, say the authors. [More]
PKC supplies Nano-Impedance Biosensor for detecting VEGF-165

PKC supplies Nano-Impedance Biosensor for detecting VEGF-165

Pharmaco-Kinesis Corporation, developer of a pre-commercialized smart implantable pump for localized cancer-fighting drug delivery, today announced its first commercialized offering, the first-generation Nano-Impedance Biosensor. [More]

Institut de France awards 2013 Grand Prix Scientifique to Penn Medicine researcher

Garret FitzGerald MD, FRS, chairman of the Pharmacology Department and director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique by the Institut de France. [More]
Modifiable lifestyle factors may prevent progression of Barrett's-related esophageal cancer

Modifiable lifestyle factors may prevent progression of Barrett's-related esophageal cancer

An estimated 20 million Americans have chronic heartburn. About 2 million of these people have Barrett's esophagus, a precancerous condition that affects the tube that carries food from the mouth to the stomach. [More]

POZEN announces submission of NDA for marketing approval of PA32540/PA8140

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140. [More]
Disinfectant mouthwashes may be effective against cancers of the mouth and throat

Disinfectant mouthwashes may be effective against cancers of the mouth and throat

Patients who suffer from gingivitis are often advised to use disinfectant mouthwashes. In the future, the active ingredients in these products could be used in a completely different area: As scientists have reported in the journal Angewandte Chemie, Chlorhexidin and Alexidin increase programmed cell death and may be effective against cancers of the mouth and throat. [More]

Large population of healthy people take Aspirin to prevent cardiovascular disease: Study

A new study out of the Faculty of Medicine & Dentistry shows a large population of healthy people are taking Aspirin to prevent cardiovascular disease, despite the fact that new literature shows it isn't as beneficial as once thought. [More]

University of Michigan Stroke Program study examines use of tPA in stroke patients

Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots. [More]

STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

EDTA chelation, high-dose vitamins/minerals may provide additional benefit for MI patients

Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
Aspirin's anti-inflammatory effects may help protect against melanoma

Aspirin's anti-inflammatory effects may help protect against melanoma

A new study has found that women who take aspirin have a reduced risk of developing melanoma-and that the longer they take it, the lower the risk. The findings suggest that aspirin's anti-inflammatory effects may help protect against this type of skin cancer. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society. [More]

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction. [More]